Effect of different monotherapies on serum nitric oxide and pulmonary functions in children with mild persistent asthma

Radwan, Z.; Yamamah, Gamal; Shaaban, Hala; Rahman, Azza M.O. Abdel; Ismaeil, Amany Abd-Elghany; Mostafa, Eman

doi:10.5114/aoms.2010.19302

Cited by 6 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with the current results, Radwan et al [21] had conducted a study to compare the effect of different monotherapies on pulmonary functions in Egyptian children suffering from mild persistent asthma, and concluded that ICS and montelukast play a significant role in controlling the pulmonary functions in children with mild persistent asthma. Before therapy, FEV1%, FVC%, PEFR%, and FEF 25-75% were 70.2, 72.9, 55.3, and 63.4%, respectively, and after therapy, the mean values were 81.5, 83.1, 67.2, and 76.1%, respectively, with a P-value of 0.0000, 0.02, 0.0005, and 0.005, respectively.…”

Section: Discussionsupporting

confidence: 89%

The effect of anti-inflammatory therapy on urinary leukotrienes in partly controlled asthmatic children

Yamamah

Radwan

Shaaban

et al. 2014

Medical Research Journal

View full text Add to dashboard Cite

Objective We aimed to assess urinary leukotriene (ULT) changes during asthma attacks and to evaluate the effect of anti-inflammatory drugs on ULT levels.Methods A randomized prospective case-control study was mediated. The study included 30 asthmatic patients (19 male and 11 female), aging 8-14 years. Patients were diagnosed as partly controlled asthmatic individuals. Twenty age-matched and sex-matched healthy children were also included as controls. Participants were subjected to thorough history taking, clinical examination, pulmonary function testing, ULTB4 assessment and blood eosinophilic count. Medical treatment for 6 weeks was mediated. Tests were repeated for evaluation. ResultsSignificant improvement was noted with regard to the spirometric parameters FEV1%, FVC%, PEFR% and FEF 25-75% (P < 0.001, 0.020, 0.0005, and 0.0005, respectively). The blood eosinophilic count decreased (P = 0.0002). ULTB4 levels decreased from 70.40 to 44.09 pg/ml (P = 0.0001) with leukotriene receptor antagonist treatment. The inhaled corticosteroid group also showed significant improvement. There was improvement in spirometric values and a better eosinophilic count in the inhaled corticosteroid group, whereas ULTB4 improvement was better in the leukotriene receptor antagonist group. Yet, the difference between the two groups did not reach a significant value.Conclusion Using the receiver-operating characteristic curve for the evaluation of asthma, ULTB4 was as a reliable marker for asthma monitoring and follow-up.

show abstract

Section: Discussionsupporting

confidence: 89%

The effect of anti-inflammatory therapy on urinary leukotrienes in partly controlled asthmatic children

Yamamah

Radwan

Shaaban

et al. 2014

Medical Research Journal

View full text Add to dashboard Cite

show abstract

“…It also can decrease the production of reactive nitrogen species (e.g. NO) in children with asthma [36,37]. …”

Section: Discussionmentioning

confidence: 99%

Effect of Montelukast Monotherapy on Oxidative Stress Parameters and DNA Damage in Children with Asthma

Dilek

Özkaya²,

Koçyiğit³

et al. 2015

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: There is ample knowledge reported in the literature about the role of oxidative stress in asthma pathogenesis. It is also known that the interaction of reactive oxygen species with DNA may result in DNA strand breaks. The aim of this study was to investigate if montelukast monotherapy affects oxidative stress and DNA damage parameters in a population of pediatric asthma patients. Methods: Group I consisted of 31 newly diagnosed asthmatic patients not taking any medication, and group II consisted of 32 patients who had been treated with montelukast for at least 6 months. Forty healthy control subjects were also enrolled in the study. Plasma total oxidant status (TOS) and total antioxidant status (TAS) were measured to assess oxidative stress. DNA damage was assessed by means of alkaline comet assay. Results: The patients in both group I and group II had statistically significant higher plasma TOS (13.1 ± 4 and 11.1 ± 4.1 μmol H₂O₂ equivalent/liter, respectively) and low TAS levels (1.4 ± 0.5 and 1.5 ± 0.5 mmol Trolox equivalent/liter, respectively) compared with the control group (TOS: 6.3 ± 3.5 μmol H₂O₂ equivalent/liter and TAS: 2.7 ± 0.6 mmol Trolox equivalent/liter; p < 0.05). DNA damage was 18.2 ± 1.0 arbitrary units (a.u.) in group I, 16.7 ± 8.2 a.u. in group II and 13.7 ± 3.4 a.u. in the control group. There were statistically significant differences only between group I and the control group (p < 0.05). Conclusions: According to the findings, montelukast therapy makes only minimal but not statistically significant improvement in all TOS, TAS and DNA damage parameters.

show abstract

“…These contribute to the airway obstruction or airway hyper-responsiveness, or both [3]. Common medications used to treat asthma are glucocorticoids, leukotriene receptor antagonists and theophylline [4]. And corticosteroids are the most effective drugs to suppress airway inflammation, mainly by reducing pro-inflammatory cytokines [5–7].…”

Section: Introductionmentioning

confidence: 99%

Experimental research The effects of budesonide on angiogenesis in a murine asthma model

Sun

Wang²,

Li³

et al. 2013

aoms

View full text Add to dashboard Cite

IntroductionThe aim of this study is to determine the effects and mechanisms of budesonide on angiogenesis in a murine asthma model.Material and methodsMurine asthma models were established and mice were divided into three groups: the model group (OVA-sensitized and challenged mice), the BUD group (budesonide-treated mice) and the PBS group (normal control mice). Mice in the BUD group were administered with inhaled budesonide (100 µg/kg) daily. The effects on airway inflammation, angiogenesis, expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) were examined.ResultsAdministration of budesonide ameliorated allergic airway inflammation (2.90 ±0.18 vs. 4.80 ±0.20, p < 0.01) and significantly reduced the percentage vascularity (0.78 ±0.14 vs. 2.83 ±0.90, p < 0.01) compared with those in the asthmatic model mice. It also reduced the expression of HIF-1α (immunohistochemistry results: 71.70 ±1.40 vs. 89.60 ±0.79, p < 0.001; western blotting results: 0.88 ±0.41 vs. 0.97 ±0.47, p < 0.05), as well as that of VEGF (immunohistochemistry results: 26.30 ±1.03 vs. 93.30 ±1.54, p < 0.001; western blotting results: 1.12 ±0.22 vs. 2.08 ±0.30, p < 0.01). Percentage vascularity had positive correlation with both HIF-1α (r = 0.785, p < 0.01) and VEGF (r = 0.693, p < 0.01) expression. Furthermore, there is positive relationship between HIF-1α and VEGF expression (r = 0.641, p < 0.05).ConclusionsThe results demonstrate that budesonide has an important inhibitory effect on angiogenesis in asthma. Inhaled administration of budesonide achieved anti-angiogenic activity through inhibition of HIF-1α and VEGF expression. The results support a potential anti-remodeling role for budesonide in the treatment of human asthma.

show abstract

Effect of different monotherapies on serum nitric oxide and pulmonary functions in children with mild persistent asthma

Cited by 6 publications

References 29 publications

The effect of anti-inflammatory therapy on urinary leukotrienes in partly controlled asthmatic children

The effect of anti-inflammatory therapy on urinary leukotrienes in partly controlled asthmatic children

Effect of Montelukast Monotherapy on Oxidative Stress Parameters and DNA Damage in Children with Asthma

Experimental research The effects of budesonide on angiogenesis in a murine asthma model

Contact Info

Product

Resources

About